The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...

Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

The FDA has approved Kisqali (ribociclib) in adults with HR-positive, HER2-negative stage II and III early breast cancer.

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free ...

This new indication also applies to Kisqali Femara Co-Pack (ribociclib with letrozole). The approval was based on data from the phase 3 NATALEE trial (NCT03701334), which enrolled 5101 adults with ...

“The FDA approval of Kisqali for this early breast cancer population, including those with NO [hasn't spread to nearby lymph ...

The drug joins abemaciclib (Verzenio) as approved CDK4/6 inhibitors in this setting, but the broader indication for ...

Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a ...

The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to treat patients with earlier stage cancer, ...

The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breast cancer. The FDA approved ribociclib (Kisqali) with an aromatase ...

Adjuvant ribociclib plus an aromatase inhibitor is now an FDA-approved treatment in HR-positive, HER2-negative stage II and ...